Is Elite Pharmaceuticals, Inc. (ELTP) a Buy, Sell, or Hold?
OTC : ELTP
Elite Pharmaceuticals, Inc.
$0.39 USD
$0.01 (4.0%)
- Volume
- 288.41K
- Average Volume
- 628.92K
- Market Capitalization
- $420.07M
- P/E Ratio
- 10.00
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.74
- Year Low
- $0.33
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $6.45
Company Overview
OTC
Nasrat Hakim
Drug Manufacturers - Specialty & Generic
Healthcare
ELTP
65
US
USD
Liquidity Metrics
0.06
6.45
-1215.99
1713.36
0.00
Sales & Valuation
$148.87M
2.82
4.24
18.41
0.02
Profitability
$0.0325
$44.87M
30.14%
38.16%
62.22%
32.45%
P/E Metrics
10.00
-0.01
-0.01
Analyst Price Target & Rating
4/5
0 Analysts
%
Financial Health Scores
8.37
6/9
$94.72M
$138.29M
$39.41M
$35.41M
Key Metrics (TTM)
-$29.37B
-197.30
-787.10
6.45
62.22%
32.33%
10.71%
5.43%
$0.29
104675 days
Company Executives
| Name | Title |
|---|---|
| Carter J. Ward CSCP | Chief Financial Officer, Secretary & Treasurer |
| Douglas Plassche | Executive Vice President of Operations |
| Kirko Kirkov | Chief Commercial Officer |
| Nasrat Hakim | Chairman, Chief Executive Officer & President |
| Dianne Will | Vice President of Investor Relations & Corporation Affairs |
| Christopher C. Dick | Head of Development |
| George Kenneth Smith | Vice President of Legal |
Poll Results
No votes yet today — be the first to share your view!
About Elite Pharmaceuticals, Inc. (OTC:ELTP) Stock
Elite Pharmaceuticals, Inc. (ELTP) is a specialized pharmaceutical company focused on the creation and manufacturing of generic medications, as well as oral, controlled-release drug formulations. Its business activities are primarily divided into two segments: Abbreviated New Drug Applications (ANDAs) for generic products and New Drug Applications (NDAs) for branded pharmaceuticals. The company's extensive product line includes drugs that it either owns, licenses, or produces through contract manufacturing. This portfolio features a variety of generic and oral-dose pharmaceutical products designed to address diverse medical needs. For instance, it offers Phentermine HCl 37.5mg tablets, marketed under the Adipex-P brand, and Phendimetrazine Tartrate 35mg tablets, known as Bontril, both util ... ized in bariatric medicine. Its offerings also extend to Naltrexone HCl 50mg tablets (Revia brand) for pain management, and Isradipine 2.5mg and 5mg capsules for cardiovascular conditions. Elite Pharmaceuticals further supplies various strengths of Oxycodone HCl immediate release tablets (5mg, 10mg, 15mg, 20mg, and 30mg) under the Roxycodone brand for pain relief, as well as Trimipramine Maleate Immediate Release antidepressant capsules (Surmontil brand). For central nervous system disorders, the company provides Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets, commonly associated with the Adderall brand. Additionally, its products include Dantrolene Sodium capsules (Dantrium brand) for muscle relaxation, SequestOX (an immediate-release Oxycodone formulation combined with Naltrexone), Loxapine Succinate capsules (Loxapine brand) for antipsychotic treatment, and a combination of Acetaminophen and Codeine Phosphate for managing mild to moderate pain, alongside various antibiotic products. Beyond its own product portfolio, Elite Pharmaceuticals also undertakes contract manufacturing of controlled-release products for external parties, covering therapeutic areas such as pain, allergies, bariatrics, and infections. The company is actively engaged in developing a new generation of opioid products specifically engineered to deter abuse. Established in 1997, Elite Pharmaceuticals, Inc. maintains its corporate headquarters in Northvale, New Jersey.
ELTP vs. CPIX: Which Pharma Stock Is the Better Buy Right Now?
2026-07-15 12:26:08
Elite Pharmaceuticals and Cumberland Pharmaceuticals follow different growth paths, but which looks more compelling now? Let's dive in.
Elite Pharmaceuticals Stock Slips Despite Record Fiscal 2026 Earnings
2026-07-03 12:31:15
ELTP delivers record fiscal 2026 results, with stronger profits, improved cash and pipeline progress supporting its expanding generics platform.
Elite Pharmaceuticals, Inc. (ELTP) Q4 2026 Earnings Call Transcript
2026-06-30 19:12:09
Elite Pharmaceuticals, Inc. (ELTP) Q4 2026 Earnings Call Transcript
2026-06-29 16:29:00
Conference Call Scheduled for Tuesday, June 30 at 11:30 AM EDT Northvale, New Jersey--(Newsfile Corp. - June 29, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced results for the fiscal year ended March 31, 2026 ("Fiscal 2026"). Consolidated revenues for Fiscal 2026 were $148.9 million, an increase of $64.8 million or approximately 77% as compared to the comparable period of the prior fiscal year.
2026-06-23 07:00:00
Financials for Fiscal Year 2026 Ended March 31, 2026 will be released on Monday, June 29, 2026 Northvale, New Jersey--(Newsfile Corp. - June 23, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that it will release its 2026 year-end financial results on Monday, June 29, 2026. Elite's management will host a live conference call on Tuesday, June 30th, at 11:30 AM EDT to discuss the company's financial and operating results and provide a general business update.
Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study
2026-06-15 07:00:00
Northvale, New Jersey--(Newsfile Corp. - June 15, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, today reported positive results from a pivotal bioequivalence study for an undisclosed anticonvulsant generic drug product. IQVIA reported branded and generic product sales for the twelve months ending April 2026 of $840 million.
2026-06-01 07:00:00
Northvale, New Jersey--(Newsfile Corp. - June 1, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, today announced that it has submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) for a generic drug product in the class of medications called anticoagulants. IQVIA reported branded product sales for the twelve months ending March 2026 of $26 billion.
Frequently Asked Questions
-
What is the current Elite Pharmaceuticals, Inc. (ELTP) stock price?
-
Elite Pharmaceuticals, Inc.(OTC:ELTP) stock price is $0.39 in the last trading session. During the trading session, ELTP stock reached the peak price of $0.74 while $0.33 was the lowest point it dropped to. The percentage change in ELTP stock occurred in the recent session was 4.0% while the dollar amount for the price change in ELTP stock was $0.01.
-
ELTP's industry and sector of operation?
-
The OTC listed ELTP is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.
-
Who are the executives of ELTP?
-
Carter J. Ward CSCP | Chief Financial Officer, Secretary & Treasurer
Douglas Plassche | Executive Vice President of Operations
Kirko Kirkov | Chief Commercial Officer
Nasrat Hakim | Chairman, Chief Executive Officer & President
Dianne Will | Vice President of Investor Relations & Corporation Affairs -
How many employees does ELTP have?
-
Number of ELTP employees currently stands at 65. ELTP operates from 165 Ludlow Avenue, Northvale, NJ 07647, US.
-
Link for ELTP official website?
-
Official Website of ELTP is: https://www.elitepharma.com
-
How do I contact ELTP?
-
ELTP could be contacted at phone #201 750 2646 and can also be accessed through its website. ELTP operates from 165 Ludlow Avenue, Northvale, NJ 07647, US.
-
How many shares of ELTP are traded daily?
-
The average number of ELTP shares traded daily for last 3 months was 628.92K.
-
What is the market cap of ELTP currently?
-
The market value of ELTP currently stands at $420.07M with its latest stock price at $0.39